{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T18:38:59Z","timestamp":1767379139122,"version":"3.48.0"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>In this work, we aimed to assess the impact of clazosentan on clinical labour time costs within Japan\u2019s value-based healthcare system using time-driven activity-based costing. Time-driven activity-based costing was employed to analyse the labour time costs associated with preventing cerebral vasospasm following aneurysmal subarachnoid haemorrhage. Time-driven activity-based costing simplifies cost analysis by utilising time as the primary cost driver. We compared two treatment approaches: conventional therapy with fasudil hydrochloride and postoperative therapy with clazosentan. Scenario and sensitivity analyses were performed to assess the impact of physicians\u2019 costs on the results. The use of clazosentan for the prevention of cerebral vasospasm significantly reduced human resource costs, particularly in cases where symptomatic vasospasm did not occur, yielding savings of approximately 51,343 yen. The greatest cost reductions were observed among nursing staff, with a 30% decrease in the absence of symptomatic vasospasm and a 15% reduction when symptomatic vasospasm was present. The cost reductions for physicians were comparatively smaller, particularly in cases where symptomatic vasospasm occurred. Sensitivity analyses indicated that clazosentan reduced overall costs by approximately 35,000\u201350,000 yen; however, costs increased in the presence of symptomatic vasospasm. Clazosentan for subarachnoid haemorrhage treatment significantly reduces human resource costs, especially in nursing staff. These findings support the potential of clazosentan for broader clinical use, given its cost-savings and clinical benefits in reducing cerebral vasospasm following aneurysmal subarachnoid haemorrhage.<\/jats:p>","DOI":"10.1371\/journal.pone.0340076","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T18:35:16Z","timestamp":1767378916000},"page":"e0340076","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A simulation study of the cost of cerebral vasospasm treatments with clazosentan: A mathematical model using time-driven activity-based costing"],"prefix":"10.1371","volume":"21","author":[{"given":"Jieyu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Kurisu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-1726","authenticated-orcid":true,"given":"Toshiya","family":"Osanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-7861","authenticated-orcid":true,"given":"Katsuhiko","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0991-0516","authenticated-orcid":true,"given":"Miki","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"1","key":"pone.0340076.ref001","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/17474930211065917","article-title":"World Stroke Organization (WSO): Global Stroke Fact Sheet 2022","volume":"17","author":"VL Feigin","year":"2022","journal-title":"Int J Stroke"},{"issue":"1","key":"pone.0340076.ref002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jamaneurol.2021.4346","article-title":"Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes","volume":"79","author":"K Toyoda","year":"2022","journal-title":"JAMA Neurol"},{"key":"pone.0340076.ref003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000475824","article-title":"Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients","volume":"44","author":"M Fujimura","year":"2017","journal-title":"Cerebrovasc Dis"},{"issue":"6","key":"pone.0340076.ref004","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3171\/2022.2.JNS212914","article-title":"Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients","volume":"137","author":"H Endo","year":"2022","journal-title":"J Neurosurg"},{"key":"pone.0340076.ref005","doi-asserted-by":"crossref","first-page":"1413632","DOI":"10.3389\/fneur.2024.1413632","article-title":"Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study","volume":"15","author":"H Sakata","year":"2024","journal-title":"Front Neurol"},{"key":"pone.0340076.ref006","author":"National Institute of Public Health (NIPH)"},{"issue":"9","key":"pone.0340076.ref007","first-page":"46","article-title":"How to solve the cost crisis in health care","volume":"89","author":"RS Kaplan","year":"2011","journal-title":"Harv Bus Rev"},{"key":"pone.0340076.ref008","author":"DA Haas"},{"issue":"12","key":"pone.0340076.ref009","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jpedsurg.2016.09.019","article-title":"Time-driven activity-based costing to identify opportunities for cost reduction in pediatric appendectomy","volume":"51","author":"YR Yu","year":"2016","journal-title":"J Pediatr Surg"},{"issue":"8","key":"pone.0340076.ref010","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s10198-019-01085-8","article-title":"An 8-step framework for implementing time-driven activity-based costing in healthcare studies","volume":"20","author":"APB da Silva Etges","year":"2019","journal-title":"Eur J Health Econ"},{"key":"pone.0340076.ref011","volume-title":"Time-Driven Activity-Based Costing: A Simpler and More Powerful Path to Higher Profits","author":"RS Kaplan","year":"2007"},{"key":"pone.0340076.ref012","author":"R Cooper"},{"issue":"6","key":"pone.0340076.ref013","first-page":"76","article-title":"Improving value with TDABC","volume":"68","author":"RS Kaplan","year":"2014","journal-title":"Healthc Financ Manage"},{"issue":"3","key":"pone.0340076.ref014","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2016-000134","article-title":"Rethinking the cost of healthcare in low-resource settings: the value of time-driven activity-based costing","volume":"1","author":"RK McBain","year":"2016","journal-title":"BMJ Glob Health"},{"issue":"1","key":"pone.0340076.ref015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.hjdsi.2014.09.007","article-title":"Measuring the cost of care in benign prostatic hyperplasia using time-driven activity-based costing (TDABC)","volume":"3","author":"AL Kaplan","year":"2015","journal-title":"Healthc (Amst)"},{"key":"pone.0340076.ref016","author":"Center for Outcomes Research and Economic Evaluation for Health (C2H), National Institute of Public Health, Ministry of Health, Labour and Welfare"},{"issue":"4","key":"pone.0340076.ref017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jcaf.22468","article-title":"Probabilistic time\u2010driven activity\u2010based costing","volume":"31","author":"MA S\u00e1nchez","year":"2020","journal-title":"J Corp Accounting Finance"},{"key":"pone.0340076.ref018","author":"Ministry of Health, Labour and Welfare"},{"issue":"7","key":"pone.0340076.ref019","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.healthpol.2017.04.013","article-title":"Time-driven activity-based costing in health care: A systematic review of the literature","volume":"121","author":"G Keel","year":"2017","journal-title":"Health Policy"},{"issue":"1","key":"pone.0340076.ref020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3171\/2024.4.JNS232191","article-title":"REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage","volume":"142","author":"SA Mayer","year":"2024","journal-title":"J Neurosurg"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T18:35:20Z","timestamp":1767378920000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340076"}},"subtitle":[],"editor":[{"given":"Anita Mitico","family":"Tanaka-Azevedo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340076","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}